CFB and diabetes mellitus: Taken together, these data provide evidence that FGF21 and the FGF19-BA pathway are significantly perturbed in severe diabetes and could represent suitable targets for the development of a new class of treatments for diabetes provided that the pro-oncogenic effects of FGF19 could be curtailed [24,25].